Entrada Therapeutics (TRDA) said Monday that the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.
The company said the 1b study is designed to evaluate ENTR-601-44's safety and tolerability in about 32 adults with DMD who are exon-44 skipping amenable.
Shares of Entrada Therapeutics were up more than 9% in recent premarket activity Monday.
Price: 14.28, Change: +1.24, Percent Change: +9.51
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。